Full Text View
Tabular View
No Study Results Posted
Related Studies
To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
This study has been completed.
Study NCT00007774   Information provided by Department of Veterans Affairs
First Received: December 29, 2000   Last Updated: February 3, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Schizoaffective Disorder
Schizophrenia
Additional conditions recognized in this trial
Psychotic Disorders
More general conditions related to this trial
Mental Disorders
Schizophrenia and Disorders with Psychotic Features
Interventions listed in this trial
Haloperidol
Olanzapine
Additional drug interventions recognized in this trial
Haloperidol decanoate
More general drug interventions related to this trial
Anti-Dyskinesia Agents
Antiemetics
Antipsychotic Agents
Autonomic Agents
Central Nervous System Agents
Central Nervous System Depressants
Dopamine Agents
Dopamine Antagonists
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Uptake Inhibitors
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
Department of Veterans Affairs
Eli Lilly and Company


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services